What it sells
CRISPR powered Diagnostics with results in minutes.
Business model breakdown
Buyer: who owns the budget?
UnverifiedUrgent care operators and clinic medical directors (US urgent-care chains and independents).
Trigger: what makes them buy now?
Up to 4 in 5 urgent-care respiratory patients leave without a definitive answer; antigen tests are inaccurate and lab PCR is slow.
Workflow: what inputs become what output?
Swab patient, load single-use cartridge into benchtop instrument, read syndromic panel result in under ten minutes before the patient leaves.
Economics: what it saves and how it charges
Instrument plus single-use cartridges for a ~$3B US urgent-care respiratory testing market; product in development, not yet cleared or for sale.
Distribution: how it reaches customers
Urgent-care channel partnership with UCPMM (300+ centers), led by VedaBio commercial team after anticipated FDA clearance; Siemens Healthineers strategic agreement.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.